Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Oct 1;98(7):1619–1625. doi: 10.1172/JCI118956

A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.

K Chu 1, S M Wu 1, T Stanley 1, D W Stafford 1, K A High 1
PMCID: PMC507595  PMID: 8833911

Abstract

The propeptide sequences of the vitamin K-dependent clotting factors serve as a recognition site for the enzyme gamma-glutamylcarboxylase, which catalyzes the carboxylation of glutamic acid residues at the NH2 terminus of the mature protein. We describe a mutation in the propeptide of Factor IX that results in warfarin sensitivity because of reduced affinity of the carboxylase for the Factor IX precursor. The proband has a Factor IX activity level of > 100% off warfarin and < 1% on warfarin, at a point where other vitamin K-dependent factors were at 30-40% activity levels. Direct sequence analysis of amplified genomic DNA from all eight exons and exon-intron junctions showed a single guanosine-->adenosine transition at nucleotide 6346 resulting in an alanine to threonine change at residue -10 in the propeptide. To define the mechanism by which the mutation resulted in warfarin sensitivity, we analyzed wild-type and mutant recombinant peptides in an in vitro carboxylation reaction. The peptides that were analyzed included the wild-type sequence, the Ala-10-->Thr sequence, and Ala-10-->Gly, a substitution based on the sequence in bone gamma-carboxyglutamic acid protein. Measurement of C02 incorporation at a range of peptide concentrations yielded a Vmax of 343 cpm/min/reaction for the wild-type peptide, and Vmax values of 638 and 726 for A-10T and A-10G respectively, a difference of only twofold. The Km values, on the other hand, showed a 33-fold difference between wild-type and the variants, with a value of 0.29 microM for wild-type, and 10.9 and 9.50 microM, respectively, for A-10T and A-10G. Similar kinetic experiments showed no substantial differences between wild-type and mutant peptides in kinetic parameters of the carboxylase-peptide complexes for reduced vitamin K. We conclude that the major defect resulting from the Factor IX Ala-l0-->Thr mutation is a reduction in affinity of the carboxylase for the mutant propeptide. These studies delineate a novel mechanism for warfarin sensitivity. In addition, the data may also explain the observation that bone Gla protein is more sensitive to warfarin than the coagulation proteins.

Full Text

The Full Text of this article is available as a PDF (240.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell G. I., Karam J. H., Rutter W. J. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci U S A. 1981 Sep;78(9):5759–5763. doi: 10.1073/pnas.78.9.5759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cheung A., Suttie J. W., Bernatowicz M. Vitamin K-dependent carboxylase: structural requirements for propeptide activation. Biochim Biophys Acta. 1990 May 31;1039(1):90–93. doi: 10.1016/0167-4838(90)90230-d. [DOI] [PubMed] [Google Scholar]
  3. Frenette P. S., Mayadas T. N., Rayburn H., Hynes R. O., Wagner D. D. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell. 1996 Feb 23;84(4):563–574. doi: 10.1016/s0092-8674(00)81032-6. [DOI] [PubMed] [Google Scholar]
  4. Giannelli F., Green P. M., Sommer S. S., Poon M. C., Ludwig M., Schwaab R., Reitsma P. H., Goossens M., Yoshioka A., Brownlee G. G. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res. 1996 Jan 1;24(1):103–118. doi: 10.1093/nar/24.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jorgensen M. J., Cantor A. B., Furie B. C., Brown C. L., Shoemaker C. B., Furie B. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell. 1987 Jan 30;48(2):185–191. doi: 10.1016/0092-8674(87)90422-3. [DOI] [PubMed] [Google Scholar]
  6. Knobloch J. E., Suttie J. W. Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X. J Biol Chem. 1987 Nov 15;262(32):15334–15337. [PubMed] [Google Scholar]
  7. Lozier J. N., Monroe D. M., Stanfield-Oakley S., Lin S. W., Smith K. J., Roberts H. R., High K. A. Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood. 1990 Mar 1;75(5):1097–1104. [PubMed] [Google Scholar]
  8. Morris D. P., Soute B. A., Vermeer C., Stafford D. W. Characterization of the purified vitamin K-dependent gamma-glutamyl carboxylase. J Biol Chem. 1993 Apr 25;268(12):8735–8742. [PubMed] [Google Scholar]
  9. Morris D. P., Stevens R. D., Wright D. J., Stafford D. W. Processive post-translational modification. Vitamin K-dependent carboxylation of a peptide substrate. J Biol Chem. 1995 Dec 22;270(51):30491–30498. doi: 10.1074/jbc.270.51.30491. [DOI] [PubMed] [Google Scholar]
  10. Pan L. C., Price P. A. The propeptide of rat bone gamma-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6109–6113. doi: 10.1073/pnas.82.18.6109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Price P. A., Kaneda Y. Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res. 1987 Apr 1;46(1):121–131. doi: 10.1016/0049-3848(87)90212-x. [DOI] [PubMed] [Google Scholar]
  12. Rabiet M. J., Jorgensen M. J., Furie B., Furie B. C. Effect of propeptide mutations on post-translational processing of factor IX. Evidence that beta-hydroxylation and gamma-carboxylation are independent events. J Biol Chem. 1987 Nov 5;262(31):14895–14898. [PubMed] [Google Scholar]
  13. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  14. Soute B. A., Ulrich M. M., Vermeer C. Vitamin K-dependent carboxylase: increased efficiency of the carboxylation reaction. Thromb Haemost. 1987 Feb 3;57(1):77–81. [PubMed] [Google Scholar]
  15. Soute B. A., Ulrich M. M., Watson A. D., Maddison J. E., Ebberink R. H., Vermeer C. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost. 1992 Nov 10;68(5):521–525. [PubMed] [Google Scholar]
  16. Stitt T. N., Conn G., Gore M., Lai C., Bruno J., Radziejewski C., Mattsson K., Fisher J., Gies D. R., Jones P. F. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995 Feb 24;80(4):661–670. doi: 10.1016/0092-8674(95)90520-0. [DOI] [PubMed] [Google Scholar]
  17. Suttie J. W. Synthesis of vitamin K-dependent proteins. FASEB J. 1993 Mar;7(5):445–452. doi: 10.1096/fasebj.7.5.8462786. [DOI] [PubMed] [Google Scholar]
  18. Thompson A. R. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. J Clin Invest. 1977 May;59(5):900–910. doi: 10.1172/JCI108712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wu S. M., Soute B. A., Vermeer C., Stafford D. W. In vitro gamma-carboxylation of a 59-residue recombinant peptide including the propeptide and the gamma-carboxyglutamic acid domain of coagulation factor IX. Effect of mutations near the propeptide cleavage site. J Biol Chem. 1990 Aug 5;265(22):13124–13129. [PubMed] [Google Scholar]
  20. Yoshitake S., Schach B. G., Foster D. C., Davie E. W., Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736–3750. doi: 10.1021/bi00335a049. [DOI] [PubMed] [Google Scholar]
  21. de Boer-van den Berg M. A., Ulrich M. M., Hemker H. C., Soute B. A., Vermeer C. Vitamin K-dependent carboxylase: the carboxylation of exogenous substrates in different systems. Biochim Biophys Acta. 1985 Sep 20;831(1):94–98. doi: 10.1016/0167-4838(85)90154-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES